LCT reports positive results from NZ Diabecell trial
27 October, 2010 by Staff WritersLiving Cell Technologies (LCT), the Australian biotech developing a porcine-based cell implant to combat diabetes, today reported that 10 of the 12 insulin-dependent diabetes patients taking part in the clinical trial of its Diabecell product in New Zealand have shown marked improvement.
Aussies give thumbs up to biotechnology
26 October, 2010 by Staff WritersA national survey to gauge how Australians feel about biotechnology has shown that the majority are strongly supportive of those efforts which lead to health and environmental benefits, while support for genetically modified (GM) food has fallen amid ongoing confusion and uncertainty.
AusBiotech 2010 Biotech Profile: Starpharma
25 October, 2010 by David BinningIn an industry obsessed with finding the next big blockbuster, Melbourne-based Starpharma is using its technology platform to steadily accumulate wins in a broad range of markets.
AusBiotech 2010 Special Feature: Incubating Success
20 October, 2010 by Tim DeanThere are benefits, tangible and intangible, to clustering life science companies together. The Thebarton Bioscience Precinct in South Australia shows how it can lend a boost not only to the companies involved, but to the entire biotech industry.
Patrys reports first patient treated in groundbreaking melanoma trial
19 October, 2010 by Staff WritersMelbourne biotech Patrys announced today that it has treated its first patient in the clinical trial of its natural human antibody PAT-SM6 for melanoma.
WEHI strikes commercial antibodies deal
19 October, 2010 by Staff WritersMelbourne’s Walter and Eliza Hall Institute (WEHI) has entered into a commercial agreement with New Jersey-based biotech BD to develop the institute’s reagents for research and diagnostic tools.
Health and medical research spending delivers “exceptional” returns: report
19 October, 2010 by Tim DeanHealth and medical research spending not only delivers economic benefits and supports highly skilled jobs, but it delivers significant savings in terms of health benefits.
AusBiotech 2010 Special Feature: State of biotechnology in Australia
19 October, 2010 by Tim DeanAfter a promising start to the year, economic instability and political uncertainties, along with stumbles by key companies, have put a dent in confidence amongst biotechs, but it’s not all bad news.
UniQuest to show off new projects at AusBiotech
18 October, 2010 by Staff WritersUniQuest, the commercialisation arm of the University of Queensland, will be showing off a host of new innovations and projects, including a cell-based therapy to combat infections in cancer patients undergoing chemotherapy.
Market report: Healthcare index slips for the week as wider market holds on
15 October, 2010 by Staff WritersThe S&P/ASX 200 Healthcare Index fell for the week while the broader market just clung onto positive territory.
Resolving the controversy over anti-aging sirtuins
15 October, 2010 by Tim DeanThey hold the promise of not only treating manifold diseases, from Type 2 diabetes, to neurodegenerative, cardiovascular and inflammatory disease, but also of extending life and improving general health.
Opinion: Why Australia should be proud of its clinical trial industry
12 October, 2010 by Staff WritersPerhaps it was the very success of the CTN scheme in making Australia an attractive location for clinical research, and the corresponding increase in the number of studies conducted here, that has led to the perceived loss of international standing because of start-up delays and congestion in the Human Research Ethics Committee (HREC) system.
Market report: Healthcare index up as wider market falls
24 September, 2010 by David BinningIn a reversal of last week's pattern, the S&P ASX/200 Healthcare Index put on a strong showing today to finish the week in positive territory while the wider market fell to snap a three week winning streak.
J&J to buy Crucell for US$2.29 billion
21 September, 2010 by Staff WritersJohnson & Johnson has offered US$2.29 billion to buy Dutch biotech Crucell NV, the two companies announced this week.
Ability for introspection linked to brain biology
19 September, 2010 by Staff WritersBritish scientists believe they have found the biological explanation for why some people are better than others at the important facility of introspection.
